| Name | Title | Contact Details |
|---|
Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation`s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical and biotechnology industries. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Medivation currently has 500+ employees located in beautiful downtown San Francisco, CA.
OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Mindstrong was founded by some of the world`s leading authorities in neuroscience, oncology, and technology. It is based on their shared vision to redefine neuropsychiatric healthcare, transforming diagnosis and delivering precision therapy. Mindstrong builds on one of the founder`s patented biomarker platform developed over years of extensive clinical R&D.
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.